Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
How COVID-19 could revolutionize the UK pharmaceutical procurement landscape: A DOAC procurement case study
Direct oral anticoagulants (DOACs) are widely used pharmaceutical products which represent a significant cost to the healthcare system. In 2021, National...